ribociclib in 1st line hr+ breast cancer treatment
Clicks: 160
ID: 149227
2018
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
30.0
/100
160 views
18 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #14 of 20 articles by views in acta histochemica supplementband
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Breast cancer is a leading oncologic disease among women worldwide. Though the achieved results in treating patients with luminal subtypes are high, there is a great demand on new approaches in this field. This article highlights the new CDK4/6 inhibitor ribociclib as well as presents clinical cases from the own clinical practice obtained during phase IIIb COMPLEEMENT trial.
| Reference Key |
zhukova2018ribociclib
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;L G Zhukova;I P Ganshina;O O Gordeeva;E V Lubennikova |
| Journal | acta histochemica supplementband |
| Year | 2018 |
| DOI |
10.26442/1815-1434_2018.2.38-41
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.